Diabetic vascular dysfunction: Links to glucose-induced reductive stress and VEGF

Microscopy Research and Technique

Volumn 57, Issue 5, 2002, Pages 390-407

  Tilton, Ronald G ^a  

^a TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

Advanced glycation endproducts; Diabetes; Growth factors; Hyperglycemia pseudohypoxia; Mitogen activated protein kinases; Protein kinase C; Reactive oxygen species; Sorbitol pathway; Vascular permeability; VEGF

Indexed keywords

ALCOHOLS; CELL ENGINEERING; CHEMICAL ACTIVATION; ENDOTHELIAL CELLS; ENZYME ACTIVITY; GLYCOSYLATION; OXYGEN;

ADVANCED GLYCATION END PRODUCTS; GROWTH FACTOR; HYPERGLYCAEMIA; HYPERGLYCEMIA PSEUDOHYPOXIUM; MITOGEN-ACTIVATED PROTEIN KINASE; PROTEIN KINASES C; REACTIVE OXYGEN SPECIES; SORBITOL PATHWAY; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR PERMEABILITY;

GLUCOSE;

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; BINDING PROTEIN; COLONY STIMULATING FACTOR 1; ENDOTHELIN; FRUCTOSE; GALECTIN; GLUCOSE; GROWTH FACTOR; HEME OXYGENASE; IDITOL DEHYDROGENASE; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SOMATOMEDIN C; SORBITOL; STRESS ACTIVATED PROTEIN KINASE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ARTICLE; DIABETES MELLITUS; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR DISEASE;

EID: 0036605475     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10092     Document Type: Article

References (160)

1. Hypoxic regulation of vascular endothelial growth factor in retinal cells
2. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective b isoform-selective inhibitor
3. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content. Vascular endothelial growth factor decreases occludin in retinal endothelial cells
4. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1
5. Molecular mechanisms of vascular permeability in diabetic retinopathy
6. Vascular endothelial growth factor and microvascular permeability
7. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm
8. Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes
9. Elevation of erythrocyte redox potential linked to galactonate biosynthesis: Elimination by Tolrestat
10. Reactive oxygen species and acute modulation of albumin microvascular leakage in the microcirculation of diabetic rats in vivo
11. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo
12. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients
13. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues
14. Glycation products and the pathogenesis of diabetic complications
15. Advanced protein glycosylation in diabetes and aging
16. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
17. Advanced glycosylation end products in diabetic renal and vascular disease
18. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart: Near-complete prevention of reperfusion contractile failure
19. Diabetes mellitus. A hypercoagulable state
20. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats
21. The protective action of pyruvate on recovery of ischemic rat heart: Comparison with other oxidizable substrates
22. B gene expression in chronic diabetes
23. Active site modification of aldose reductase by nitric oxide donors
24. Advanced glycation end products, oxidant stress and vascular lesions
25. Endothelin and pulmonary hypertension
26. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase and senile cataractogenesis
27. Simultaneous measurement of ERK, p38, and JNK MAP kinase cascades in vascular smooth muscle cells
28. MAP kinase pathways
29. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose
30. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids
31. Modulation of venular microvessel permeability by calcium influx into endothelial cells
32. Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients
33. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
34. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
35. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats
36. Effects on rat renal osmolytes of extended treatment with an aldose reductase inhibitor
37. Inceased NADH oxidase activity in the retina of the BBZ/W or diabetic rat
38. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs
39. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats
40. Vascular endothelial growth factor
41. In human erythrocytes galactose induces greater imbalances in glycolysis than glucose
42. The aldose reductase controversy
43. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia
44. Advanced glycation endproducts interacting with their receptors activate vascular smooth muscle cells: Induction of chemoattractants for smooth muscle cells and monocytes
45. Similarities between the oxygen sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
46. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy
47. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells
48. Occludin as a possible determinant of tight junction permeability in endothelial cells
49. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Müller cells
50. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
51. From receptors to stress-activated MAP kinases
52. Interactions between the sorbitol pathway, non-enzymatic glycation and diabetic vascular dysfunction
53. Inhibitors of sorbitol dehydrogenase (SDI) and aldose reductase (ARI) reverse impaired motor nerve conduction velocity (MNCV) in diabetic rats
54. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C
55. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways
56. Preferential elevation of protein kinase C isoform âll and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
57. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
58. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
59. Amelioration of diabetes-like retinal changes in galactose-fed dogs
60. Stimulation of MAPK cascades by insulin and osmotic shock. Lack of an involvement of p38 mitogen-activated protein kinase in glucose transport in 3T3-L1 adipocytes
61. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-êB activation in endothelial cells
62. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes
63. The involvement of aldose reductase in diabetic complications
64. ε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expession
65. Protein kinase C activation and the development of diabetic complications
66. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
67. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo
68. Mammalian mitogen-activated protein kinases signal transduction pathways acivated by stress and inflammation
69. Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart
70. Antioxidants, diabetes and endothelial dysfunction
71. Metabolism of fructose 3-phosphate in the diabetic rat lens
72. Activation of the receptor for advanced glycation end products triggers a p21 (ras)-dependent mitogen activated protein kinase pathway regulated by oxidant stress
73. Contribution of polyol pathway to oxidative stress in diabetic cataract
74. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications
75. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
76. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif
77. 2+ homeostasis in diabetes mellitus
78. B-crystallin, and organic osmolytes in the retinal pigment epithelium
79. Glutathione depletion in the lens of galactosemic and diabetic rats
80. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy
81. Advanced glycation end products increase retinal vascular endothelial growth factor expression
82. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs
83. Vascular endothelial growth factor activates nuclear factor-kappa B and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells
84. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression
85. Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver
86. Pathogenetic potential of leukocytes in diabetic retinopathy
87. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition
88. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)
89. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis
90. Alteration in non-enzymatic biochemistry in uraemia: Origin and significance of "carbonyl stress" in long term uraemic complications
91. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels
92. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas
93. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
94. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli
95. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
96. Protein kinase C and myocardial biology and function
97. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
98. Regulation of protein kinase C
99. Normalizing mitochondrial superoxide production blocks three pathways of hypergylcaemic damage
100. The missing link: A single unifying mechanism for diabetic complications
101. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
102. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis
103. Aldose reductase inhibitors: Therapeutic implications for diabetic complications
104. Interaction between osmotic and oxidative stress in diabetic precataractous lens
105. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: A prevention study
106. Diabetes-induced changes in retinal NAD-redox status
107. Induction of endothelin-1 expression by glucose. An effect of protein kinase C activation
108. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
109. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion
110. Intense focal expression of vascular endothelial growth factor mRNA in human intracranial neoplasms: Association with regions of necrosis
111. Vascular filtration function in galactose-fed versus diabetic rats: The role of polyol pathway activity
112. Endothelin 1 transcription is controlled by nuclear Factor-[kappa]B in AGE-stimulated cultured endothelial cells
113. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men
114. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells
115. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface
116. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
117. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice
118. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
119. Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-β as a key modulator
120. Reversible oxidant-induced increases in albumin transfer across cultured endothelium: Alterations in cell shape and calcium homeostasis
121. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
122. 2 increase in endothelial permeability
123. Advanced glycation endproducts stimulate the MAP-kinase pathway in tubulus cell line LLC-PK1
124. Effect of glycated proteins on the matrix of glomerular epithelial cells
125. Advanced glycation endproducts: A review
126. Advanced Maillard reaction end products are associated with Alzheimer disease pathology
127. Depostion of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat
128. Angiogenic effects of advanced glycation end products of the Maillard reaction on cultured human umbilical cord vein endothelial cells
129. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs
130. Pericyte degeneration and acellular capillaries are increased in the feet of human diabetic patients
131. +
132. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats
133. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
134. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF
135. Mitogen-activated protein kinases as glucose transducers for diabetic complications
136. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism
137. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets
138. Advanced glycation end-products contribute to amyloidosis in Alzheimer disease
139. Recent progress in advanced glycation end products and diabetic complications
140. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
141. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
142. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly
143. The cellular response to oxidative stress: Influences of mitogen-activated protein kinase signalling pathways on cell survival
144. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
145. Glucose-induced vascular smooth muscle dysfunction: The role of protein kinase C
146. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
147. Hyperglycemic pseudohypoxia and hypoxia in the pathogenesis of diabetic complications
148. Hyperglycemic pseudohypoxia and diabetic complications
149. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels
150. Reactive oxygen species and vascular signal transduction mechanisms
151. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
152. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
153. Advanced glycation end products-driven angiogensis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor
154. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
155. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
156. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
157. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance
158. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: Relationship to macrophage receptor for glucose-modified proteins
159. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kB transcriptional activation and cytokine secretion
160. Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade